Enterprise Value
-25.75M
Cash
221.1M
Avg Qtr Burn
-33.91M
Short % of Float
5.68%
Insider Ownership
4.35%
Institutional Own.
89.56%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Phase 2b Data readout | ||
Phase 2 Data readout | ||
AK006 Details Chronic urticaria | Phase 1 Initiation | |
Lirentelimab (AK002) (Siglec-8) Details Eosinophilic Esophagitis | Failed Discontinued | |
Lirentelimab (AK002) (Siglec-8) Details Eosinophilic Duodentitis , Eosinophilic Gastritis | Failed Discontinued |